Erectile dysfunction has more treatment options than sildenafil or tadalafil tablets. Oral PDE5 inhibitors are common evidence-based treatments, but some patients have contraindications, inadequate response or a preference for nonoral approaches. Clinician-supervised alprostadil injections, vacuum erection devices, appropriately selected surgical implants, management of contributing conditions and psychosexual counseling are distinct options with different requirements, benefits and risks. The former MUSE intraurethral alprostadil system is relevant historically, but its U.S. presentations were discontinued and should not be listed as a currently obtainable treatment.
Choice begins with understanding the cause and circumstances of ED. Cardiovascular and metabolic health, medications, symptoms, relationship factors and prior response may all matter. A strategy that suits one person may not suit another; an injection, implant or device must not be portrayed as simply a “stronger pill.” A proper evaluation also determines whether the person is medically fit for sexual activity.
This page compares treatment modalities, not a route to purchase individual injectable drugs. The erectile dysfunction guide covers the condition itself, the oral ED medication catalog covers tablets, and the alprostadil access page addresses prescription/pharmacy questions without providing self-injection directions.
Each therapy has a different mechanism and risk profile. The table describes categories, not personalized treatment recommendations or head-to-head superiority. A patient can discuss several approaches without assuming they must be combined.
Some procedures require specialist training and follow-up, while lifestyle and counseling approaches may be relevant alongside medical treatment. Use a clinician’s assessment to decide which paths are appropriate.
| Approach | Main practical feature | Professional consideration |
|---|---|---|
| Oral PDE5 prescription drugs | Tablets taken according to approved instructions | Nitrates, riociguat, interactions and cardiac fitness |
| Alprostadil injection therapy | Local vasoactive medicine in a supervised treatment framework | Prescription, individualized training and priapism risk |
| Historical MUSE urethral alprostadil | Previously approved transurethral treatment; U.S. presentations discontinued | Not a current U.S. pharmacy option; different from injections |
| Vacuum erection device | Mechanical, non-drug approach | Proper selection, comfort and device safety |
| Penile prosthesis | Surgical option for selected patients | Specialist evaluation, surgical risks and permanence |
| Lifestyle, disease management and counseling | Addresses relevant physical and psychosocial contributors | Ongoing care matched to underlying causes |
Sildenafil, tadalafil, vardenafil and avanafil are FDA-approved oral ED drugs. They facilitate erectile response to stimulation and have different timing, food, dosage-form and medication-interaction considerations. Tadalafil additionally has distinct daily and as-needed ED prescribing frameworks.
PDE5 medicines are contraindicated with nitrates and soluble guanylate cyclase stimulators such as riociguat. The clinician must consider cardiovascular health, other medicines and adverse-effect history. The sildenafil–tadalafil comparison explains one common active-ingredient decision without treating tablets as interchangeable.
Prescription intracavernosal alprostadil may be considered by an ED specialist, particularly when oral treatment is unsuitable or ineffective. Unlike PDE5 tablets, it uses a local drug-delivery approach and involves specific risks such as penile pain, bleeding or bruising, priapism and other complications.
Patients need appropriate medical evaluation and hands-on clinical instruction. This page intentionally provides no injection preparation, site-selection, needle technique or dose-selection directions. The alprostadil pharmacy guide addresses legitimate prescription product access, not unsupervised self-treatment.
MUSE (alprostadil) was an FDA-approved medicated urethral system for erectile dysfunction, delivered by a different route from intracavernosal Caverject or Edex injections. According to the American Society of Health-System Pharmacists drug-shortage record, Viatris discontinued all U.S. MUSE urethral suppository presentations. Historic prescribing information remains useful for explaining the treatment modality, but it should not be read as evidence of current pharmacy supply.
Distinguish a discontinued brand from other alprostadil formulations: the same active substance does not make an injectable vial, device-based cartridge and urethral system interchangeable. Readers interested in nonoral ED care should ask a qualified specialist about options that are genuinely available and medically appropriate. This page does not instruct patients to source discontinued products, import substitutes or use an injection by themselves.
A vacuum erection device uses a mechanical method rather than an oral vascular-signaling drug. It may be an option when a patient prefers a non-drug approach or cannot take PDE5 inhibitors, but suitability and comfort require proper device selection and professional advice.
Device use can involve discomfort, bruising or restrictions for people with bleeding risks or other conditions. The equipment’s instructions and a clinician’s recommendations matter. Device treatment should not be presented as universally harmless or equivalent to the results of medication.
Penile prostheses may be considered for selected patients after careful discussion of alternatives and expected outcomes. Types and procedure considerations vary, but any implanted device involves surgery, infection and mechanical risks, future revision possibilities and an informed-consent process.
A surgical pathway is different from filling a prescription or choosing a tablet strength. Urological specialist evaluation, realistic expectations and follow-up are essential. Online retail claims should not substitute for a qualified surgical assessment.
ED can involve performance anxiety, relationship stress, depression, other psychological contributors or a combination with physical illness. Appropriate counseling or sex therapy may be useful either independently or alongside medically indicated treatment, depending on the person’s circumstances.
This does not mean persistent ED is “only psychological” or that counseling replaces evaluation for cardiovascular, endocrine or medication-related causes. A good treatment plan can address physical and emotional contributors without oversimplifying either.
Addressing smoking, inactivity, cardiovascular risk factors, diabetes management, sleep issues and medication effects may be relevant to ED care. Changes should be tailored to the patient, especially when the underlying illness requires prescribed treatment. Do not stop blood-pressure or other medicines independently because of sexual side effects.
When appropriate, a clinician may investigate hormonal issues. Testosterone therapy is not a routine ED substitute without a supported diagnosis and assessment of risks. A broad “men’s health” advertisement cannot establish that a hormone product is needed.
Any prescription choice requires product-specific warnings. For oral PDE5 drugs, the nitrate and riociguat contraindications are especially important. Injection therapies have their own local and prolonged-erection hazards; devices and surgery have distinct mechanical or procedural risks.
An erection lasting more than four hours requires emergency care, regardless of which ED treatment preceded it. Sudden significant adverse symptoms should never be managed solely through a product FAQ. Professional training, clear follow-up and access to appropriate urgent care are part of safe treatment.
Oral prescriptions, pharmacy-dispensed injections, reusable devices, specialist appointments, procedural care and counseling may generate different cost components. Coverage varies by plan and indication, and some services may involve separate training or administration charges.
No universal cheapest treatment can be identified by comparing tablet advertisements with device or surgical fees. Ask the relevant licensed provider, pharmacy or insurer for current all-in estimates for clinically suitable options. The oral medication cost comparison addresses only the narrower drug category.
If oral treatment fails, review whether it was taken as prescribed, whether stimulation and expectations were appropriate, whether interactions or medical conditions affected response, and whether the diagnosis needs further evaluation. Simply increasing medicine or ordering another product online may introduce harm.
An experienced clinician can discuss alternative modalities, referrals, patient preferences and necessary training. The right next step may be an adjusted plan, specialist consultation or a non-drug intervention rather than a new online medicine order.
No. Prescription alprostadil approaches, vacuum devices, selected surgical treatments, counseling and management of contributing conditions may be considered.
No. Injectable alprostadil requires legitimate prescribing and appropriate professional instruction and monitoring.
No. They are mechanical devices and have a different set of use and safety considerations.
Yes. Prostheses are surgical treatments requiring specialist assessment and informed consent.
The former FDA-approved MUSE urethral product is discontinued in the United States. Historic product labels do not establish current supply; a clinician can discuss presently available alternatives.
No. Hormone treatment requires a medically supported indication and appropriate risk assessment.
Counseling may help when psychological or relationship factors contribute, alone or alongside indicated medical care.
Discuss response, use conditions and potential alternatives with a clinician; do not independently increase doses or combine treatments.